Cencora Inc. Q4 2026 Earnings Recap

Cencora shares rose 4.0% after earnings, with investors responding to fiscal 26 adjusted operating income growth of 14% and adjusted EPS growth of 12%. The outlook for fiscal 27 reflects confidence, though management flagged near-term financial headwinds from divestitures.

Key Takeaways

• Fiscal 26 adjusted diluted EPS was $17.97, up 12%; adjusted operating income grew 14%.
• Specialty growth is a strategic focus: management said the market grew at twice the rate of the broader market over the past five years.
• Cencora completed its OneOncology acquisition and announced additions to its MSO platform, including iSouth Retina and an agreement to acquire a majority interest in American Oncology Network.
• The company entered into agreements or completed divestitures for all businesses in “other,” freeing resources for its pharmaceutical-centric strategy but creating near-term financial headwinds.
• A new operating model introduces two reporting segments: Specialty Pharmaceutical and Provider Services, and Pharmaceutical Distribution and Services.